首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Development and validation of an LC-MS/MS method for the determination of pelubiprofen and its active metabolite, trans-alcohol, in human plasma and its application to pharmacokinetic study
【24h】

Development and validation of an LC-MS/MS method for the determination of pelubiprofen and its active metabolite, trans-alcohol, in human plasma and its application to pharmacokinetic study

机译:LC-MS / MS法测定人血浆中培比洛芬及其活性代谢产物反式醇的开发与验证及其在药代动力学研究中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

A suitable liquid chromatography tandem mass spectrometry (LC-MS/MS) method is required to determine pelubiprofen and its active metabolite, trans-alcohol (M-D), in human plasma for pharmacokinetic studies of pelubiprofen preparations. After one-step liquid-liquid extraction (LLE) using methyl tertbutyl ether (MTBE), pelubiprofen, M-D, and tolbutamide (the internal standard, IS) were eluted from a Capcellpak C-18 ACR column using a gradient mobile phase consisting of 0.1% formic acid in water and acetonitrile at a flow rate 0.35 mL/min. The achieved lower limits of quantitation (LLOQ) of pelubiprofen and M-D were both 15 ng/mL (S/N >10) and the standard calibration curves for pelubiprofen and M-D were linear (correlation coefficients >0.99) over the studied concentration range (15-2000 ng/mL). Intra- and inter-day precisions were within 7.62% for all analytes and the deviation of assay accuracies was within +/- 13.23%. The developed method was successfully applied to a pharmacokinetic study of pelubiprofen in healthy Korean male volunteers. (C) 2015 Elsevier B.V. All rights reserved.
机译:需要一种合适的液相色谱串联质谱(LC-MS / MS)方法来测定人血浆中的pelubiprofen及其活性代谢物反式醇(M-D),以进行pelubiprofen制剂的药代动力学研究。在使用甲基叔丁基醚(MTBE)进行一步液-液萃取(LLE)后,使用由0.1组成的梯度流动相从Capcellpak C-18 ACR色谱柱洗脱pelubiprofen,MD和甲苯磺丁脲(内标,IS)。在水和乙腈中的%甲酸,流速为0.35 mL / min。在研究浓度范围内(15),pelubiprofen和MD的定量下限(LLOQ)均为15 ng / mL(S / N> 10),pelubiprofen和MD的标准校准曲线为线性(相关系数> 0.99) -2000 ng / mL)。所有分析物的日内和日间精确度在7.62%之内,测定准确度偏差在+/- 13.23%之内。所开发的方法已成功地应用于pelubiprofen在健康的韩国男性志愿者中的药代动力学研究。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号